TRCT
AUPH icon

Tower Research Capital (TRC)’s Aurinia Pharmaceuticals AUPH Stock Holding History

Tower Research Capital (TRC)’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$197K Buy
13,314
+9,863
+286% +$144K 0.01% 1629
2025
Q4 		$55K Sell
3,451
-6,002
-63% -$85.1K ﹤0.01% 2346
2025
Q3 		$104K Sell
9,453
-11,093
-54% -$121K ﹤0.01% 1956
2025
Q2 		$174K Buy
20,546
+15,591
+315% +$125K ﹤0.01% 1917
2025
Q1 		$39.8K Buy
4,955
+1,605
+48% +$13K ﹤0.01% 2387
2024
Q4 		$30.1K Buy
3,350
+2,635
+369% +$21.5K ﹤0.01% 2902
2024
Q3 		$5.24K Sell
715
-25,992
-97% -$161K ﹤0.01% 4306
2024
Q2 		$152K Buy
26,707
+17,717
+197% +$93.3K ﹤0.01% 2275
2024
Q1 		$45K Sell
8,990
-13,527
-60% -$91.8K ﹤0.01% 2356
2023
Q4 		$202K Buy
22,517
+19,453
+635% +$160K ﹤0.01% 2090
2023
Q3 		$23.8K Sell
3,064
-3,326
-52% -$32.5K ﹤0.01% 3214
2023
Q2 		$61.9K Buy
6,390
+2,629
+70% +$27.3K ﹤0.01% 2410
2023
Q1 		$41K Sell
3,761
-27,751
-88% -$244K ﹤0.01% 2670
2022
Q4 		$136K Buy
31,512
+24,609
+356% +$143K 0.01% 1583
2022
Q3 		$52K Sell
6,903
-10,150
-60% -$87.9K ﹤0.01% 3124
2022
Q2 		$171K Buy
17,053
+2,959
+21% +$33.1K ﹤0.01% 1885
2022
Q1 		$174K Buy
14,094
+2,573
+22% +$39.8K ﹤0.01% 1833
2021
Q4 		$263K Buy
11,521
+8,308
+259% +$197K ﹤0.01% 1560
2021
Q3 		$71K Sell
3,213
-5,729
-64% -$90.9K ﹤0.01% 2674
2021
Q2 		$116K Buy
8,942
+7,314
+449% +$93.2K ﹤0.01% 2310
2021
Q1 		$21K Sell
1,628
-1,152
-41% -$16.7K ﹤0.01% 3830
2020
Q4 		$38K Sell
2,780
-877
-24% -$12.8K ﹤0.01% 3364
2020
Q3 		$54K Buy
3,657
+2,281
+166% +$33K ﹤0.01% 3503
2020
Q2 		$22K Buy
+1,376
New +$22K ﹤0.01% 3620
2020
Q1 		– Sell
-4,339
Closed -$87K – 3030
2019
Q4 		$87K Sell
4,339
-4,043
-48% -$37.2K 0.01% 1019
2019
Q3 		$45K Buy
8,382
+7,234
+630% +$43.8K ﹤0.01% 1861
2019
Q2 		$7K Sell
1,148
-152
-12% -$969 ﹤0.01% 2747
2019
Q1 		$8K Sell
1,300
-300
-19% -$1.99K ﹤0.01% 2786
2018
Q4 		$11K Buy
1,600
+1,200
+300% +$6.92K ﹤0.01% 2371
2018
Q3 		$3K Buy
+400
New +$2.24K ﹤0.01% 3276
2018
Q2 		– Sell
-3,273
Closed -$18K – 3623
2018
Q1 		$18K Sell
3,273
-1,086
-25% -$5.81K ﹤0.01% 2213
2017
Q4 		$25K Buy
4,359
+1,859
+74% +$10.3K ﹤0.01% 1872
2017
Q3 		$20K Hold
2,500
– – ﹤0.01% 2718
2017
Q2 		$20K Buy
2,500
+200
+9% +$1.35K ﹤0.01% 1208
2017
Q1 		$17K Buy
+2,300
New +$10.6K ﹤0.01% 1383
2016
Q3 		– Sell
-1,000
Closed -$4K – 3608
2016
Q2 		$4K Buy
1,000
+700
+233% +$1.91K ﹤0.01% 3493
2016
Q1 		$1K Sell
300
-7,467
-96% -$18.1K ﹤0.01% 3632
2015
Q4 		$19K Buy
7,767
+7,167
+1,195% +$19.5K ﹤0.01% 1332
2015
Q3 		$2K Sell
600
-3,100
-84% -$10.6K ﹤0.01% 3300
2015
Q2 		$14K Buy
3,700
+500
+16% +$1.86K ﹤0.01% 2396
2015
Q1 		$18K Buy
3,200
+152
+5% +$603 ﹤0.01% 2326
2014
Q4 		$11K Buy
3,048
+1,448
+91% +$5.16K ﹤0.01% 2048
2014
Q3 		$5K Buy
+1,600
New +$5.69K ﹤0.01% 3261

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Tower Research Capital (TRC)'s AUPH Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Aurinia Pharmaceuticals (AUPH) stake by 286% in Q1 2026, buying an estimated $144K and bringing the position to 13,314 shares worth $197K. The position accounts for 0.01% of the portfolio, ranked #1629.

Tower Research Capital (TRC) first reported a position in AUPH in Q3 2014 and has held it in 43 quarters since. The position peaked at $263K in Q4 2021. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Tower Research Capital (TRC) held 13,314 shares of Aurinia Pharmaceuticals worth $197K as of Q1 2026.
  • Tower Research Capital (TRC) bought 9,863 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $144K.
  • Aurinia Pharmaceuticals made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1629 holding.
  • Tower Research Capital (TRC) first reported a position in Aurinia Pharmaceuticals in Q3 2014 and has held it in 43 quarters since.
  • Tower Research Capital (TRC)'s Aurinia Pharmaceuticals position peaked at $263K in Q4 2021.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.